PMID- 37556239
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230829
IS  - 2574-0970 (Electronic)
IS  - 2574-0970 (Linking)
VI  - 3
IP  - 9
DP  - 2020 Sep 25
TI  - Nanoparticle-Based Strategies to Combat COVID-19.
PG  - 8557-8580
LID - 10.1021/acsanm.0c01978 [doi]
AB  - Coronavirus disease 2019 (COVID-19) is the worst pandemic disease of the current 
      millennium. This disease is caused by the highly contagious severe acute 
      respiratory syndrome coronavirus 2 (SARS-CoV-2), which first exhibited 
      human-to-human transmission in December 2019 and has infected millions of people 
      within months across 213 different countries. Its ability to be transmitted by 
      asymptomatic carriers has put a massive strain on the currently available testing 
      resources. Currently, there are no clinically proven therapeutic methods that 
      clearly inhibit the effects of this virus, and COVID-19 vaccines are still in the 
      development phase. Strategies need to be explored to expand testing capacities, 
      to develop effective therapeutics, and to develop safe vaccines that provide 
      lasting immunity. Nanoparticles (NPs) have been widely used in many medical 
      applications, such as biosensing, drug delivery, imaging, and antimicrobial 
      treatment. SARS-CoV-2 is an enveloped virus with particle-like characteristics 
      and a diameter of 60-140 nm. Synthetic NPs can closely mimic the virus and 
      interact strongly with its proteins due to their morphological similarities. 
      Hence, NP-based strategies for tackling this virus have immense potential. NPs 
      have been previously found to be effective tools against many viruses, especially 
      against those from the Coronaviridae family. This Review outlines the role of NPs 
      in diagnostics, therapeutics, and vaccination for the other two epidemic 
      coronaviruses, the 2003 severe acute respiratory syndrome (SARS) virus and the 
      2012 Middle East respiratory syndrome (MERS) virus. We also highlight 
      nanomaterial-based approaches to address other coronaviruses, such as human 
      coronaviruses (HCoVs); feline coronavirus (FCoV); avian coronavirus infectious 
      bronchitis virus (IBV); coronavirus models, such as porcine epidemic diarrhea 
      virus (PEDV), porcine reproductive and respiratory syndrome virus (PRRSV), and 
      transmissible gastroenteritis virus (TGEV); and other viruses that share 
      similarities with SARS-CoV-2. This Review combines the salient principles from 
      previous antiviral studies with recent research conducted on SARS-CoV-2 to 
      outline NP-based strategies that can be used to combat COVID-19 and similar 
      pandemics in the future.
CI  - Copyright (c) 2020 American Chemical Society.
FAU - Medhi, Riddhiman
AU  - Medhi R
AUID- ORCID: 0000-0002-2368-2468
AD  - Department of Chemistry and the Texas Center for Superconductivity, University of 
      Houston, 4800 Calhoun Road, Houston, Texas 77204-5003, United States.
FAU - Srinoi, Pannaree
AU  - Srinoi P
AUID- ORCID: 0000-0003-4400-468X
AD  - Department of Chemistry and the Texas Center for Superconductivity, University of 
      Houston, 4800 Calhoun Road, Houston, Texas 77204-5003, United States.
FAU - Ngo, Nhat
AU  - Ngo N
AUID- ORCID: 0000-0001-5710-1601
AD  - Department of Chemistry and the Texas Center for Superconductivity, University of 
      Houston, 4800 Calhoun Road, Houston, Texas 77204-5003, United States.
FAU - Tran, Hung-Vu
AU  - Tran HV
AUID- ORCID: 0000-0001-8536-2737
AD  - Department of Chemistry and the Texas Center for Superconductivity, University of 
      Houston, 4800 Calhoun Road, Houston, Texas 77204-5003, United States.
FAU - Lee, T Randall
AU  - Lee TR
AUID- ORCID: 0000-0001-9584-8861
AD  - Department of Chemistry and the Texas Center for Superconductivity, University of 
      Houston, 4800 Calhoun Road, Houston, Texas 77204-5003, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200825
PL  - United States
TA  - ACS Appl Nano Mater
JT  - ACS applied nano materials
JID - 101726750
COIS- The authors declare no competing financial interest.
EDAT- 2020/08/25 00:00
MHDA- 2020/08/25 00:01
CRDT- 2023/08/09 12:13
PHST- 2020/07/21 00:00 [received]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/08/25 00:01 [medline]
PHST- 2020/08/25 00:00 [pubmed]
PHST- 2023/08/09 12:13 [entrez]
AID - 10.1021/acsanm.0c01978 [doi]
PST - epublish
SO  - ACS Appl Nano Mater. 2020 Aug 25;3(9):8557-8580. doi: 10.1021/acsanm.0c01978. 
      eCollection 2020 Sep 25.